SLR Investment Corp. Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Portfolio Shift: Continued shift towards specialty finance strategies for more attractive risk-adjusted returns, leveraging underlying collateral for downside protection.
• Originations: Record Q2 originations with $567 million of new investments and $387 million of repayments, resulting in comprehensive portfolio growth to $3.2 billion.
• Credit Quality: 95.9% of the comprehensive investment portfolio consisted of first lien senior secured loans, 99.5% of debt investments performing, and de minimis PIK income.
• Infrastructure: 5 commercial finance affiliates for servicing, 320-person team, and expanded origination funnel across 20 regional offices.
• Yield and Allocation: Weighted average yield on the comprehensive portfolio was 12.2%, with 83% of the portfolio derived from specialty finance investments and 16.9% from cash flow sponsor-backed loans.

Segment Performance

• Asset-Based Lending: At quarter end, the ABL portfolio totaled over $1.3 billion across 259 borrowers, representing approximately 42% of the comprehensive portfolio. SLR originated $373 million of new ABL investments in the second quarter, with a weighted average asset level yield of 13.4% (Q2) compared to 13.8% in Q1.
• Equipment Finance: The portfolio totaled just over $1 billion, representing just under 33% of the comprehensive portfolio. Originated just over $140 million of new assets in Q2, with a weighted average asset level yield of 11.6%, consistent with Q1.
• Life Sciences: The life science portfolio totaled approximately $215 million across 9 borrowers, representing just under 7% of the comprehensive portfolio and contributing 12% of gross investment income. Originated approximately $30 million of new investments in Q2, with a weighted average yield on the first lien portfolio of 13.1% (inclusive of potential success fees).
• Sponsor Finance: The sponsor finance portfolio totaled just under $550 million across 33 borrowers. The weighted average yield on the cash flow portfolio was 10.3% in Q2, down from 10.4% in Q1. The SSLP earned total income of $1.1 million in Q2, with $32 million of new investments and $14 million of repayments.

Guidance

• Dividend: The Board declared a Q3 2025 quarterly base distribution of $0.41 per share.
• Deployment: Over $650 million available capital to deploy, focusing on rotating to higher-yielding assets.
• Rate Impact: Specialty finance strategies expected to have less correlation with base rates, providing cushion against potential spread compression.

Risks

• Economic Uncertainty: Impact of tariffs, interest rates, and supply-demand imbalance in sponsor finance.
• Regulatory Changes: Potential impact on regional banks and ABL market dynamics due to changing capital rules.
• Sector-Specific: Life sciences face challenges from FDA/NIH cuts, evolving public policy, and valuation issues.

Question and Answer

Q: What was the average yield on new originations and impact on net investment income?

A: New originations had an average yield of 11.8%, exits averaged over 10%. If new originations were deployed for a full quarter, there would have been full dividend coverage.

Q: Could regional bank capital rules lead to them returning to the ABL market?

A: No signs of relief, and banks face barriers to entry making it difficult to reenter quickly.

Q: How does leverage and potential rate cuts impact earnings power?

A: Over $600 million of dry powder, focus on rotating to higher-yielding assets; specialty finance less correlated with base rates.

Q: What's driving the SSLP income and equipment finance portfolio changes?

A: SSLP income ebbed due to asset repayments; equipment finance portfolio shrinking but starting to rebuild with a pivot to investment-grade leasing.